Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease

References

• Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology. 2005;42:44–52.
   PubMed Web of Science ®Google Scholar
• Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.
   PubMed Web of Science ®Google Scholar
• Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol. 2009;8:S18–S24.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55:2005–2023.
   PubMed Web of Science ®Google Scholar
• Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112.
   PubMed Web of Science ®Google Scholar
• Staub F, Tournoux-Facon C, Roumy J, et al. Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring. Eur Radiol. 2009;19:1991–1997.
   PubMed Web of Science ®Google Scholar
• Zoli M, Magalotti D, Bianchi G, et al. Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. J Hepatol. 1995;23:129–134.
   PubMed Web of Science ®Google Scholar
• Agustí AG, Roca J, Bosch J, et al. The lung in patients with cirrhosis. J Hepatol. 1990;10:251–257.
   PubMed Web of Science ®Google Scholar
• Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther. 2001;89:221–231.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Lim JK, Lim J, Program MoVAHCRC. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program. Am J Gastroenterol. 2009;104:1802–1829.
   PubMed Web of Science ®Google Scholar
• Desser TS, Sze DY, Jeffrey RB. Imaging and intervention in the hepatic veins. AJR Am J Roentgenol. 2003;180:1583–1591.
   PubMed Web of Science ®Google Scholar
• Bernatik T, Strobel D, Hahn EG, et al. Doppler measurements: a surrogate marker of liver fibrosis? Eur J Gastroenterol Hepatol. 2002;14:383–387.
   PubMed Web of Science ®Google Scholar
• Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the French association for the study of the liver (AFEF). Hepatology. 2000;32:477–481.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 2002;36:S57–S64.
   PubMedGoogle Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854.
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
   PubMed Web of Science ®Google Scholar
• McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–1269.
   PubMed Web of Science ®Google Scholar
• Islam S, Antonsson L, Westin J, et al. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005;40:867–872.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–1447.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.
   PubMed Web of Science ®Google Scholar
• Mathiesen UL, Franzén LE, Frydén A, et al. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol. 1999;34:85–91.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474.
   PubMed Web of Science ®Google Scholar
• Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–1417.
   PubMed Web of Science ®Google Scholar
• Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet. 1999;353:1579–1583.
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Kaneko T, Hirota M, et al. Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intrahepatic hemodynamic changes accompanying cirrhosis. J Hepatol. 2002;37:578–583.
   PubMed Web of Science ®Google Scholar
• Blomley MJ, Lim AK, Harvey CJ, et al. Liver microbubble transit time compared with histology and child-pugh score in diffuse liver disease: a cross sectional study. Gut. 2003;52:1188–1193.
   PubMed Web of Science ®Google Scholar
• Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut. 2005;54:128–133.
   PubMed Web of Science ®Google Scholar
• Giuseppetti GM, Argalia G, Abbattista T. Liver cirrhosis: evaluation of haemodynamic changes using an ultrasound contrast agent. Eur J Radiol. 2004;51:27–33.
   PubMed Web of Science ®Google Scholar
• Cocciolillo S, Parruti G, Marzio L. CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. World J Hepatol. 2014;6:496–503.
   PubMedGoogle Scholar
• Berzigotti A, Piscaglia F. Ultrasound in portal hypertension-part 1. Ultraschall Med. 2011;32:548–568. quiz 69–71.
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Piscaglia F. Committee EEaPS. Ultrasound in portal hypertension–part 2–and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension. Ultraschall Med. 2012;33:8–32. quiz 0–1.
   PubMed Web of Science ®Google Scholar
• Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver – update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39:187–210.
   PubMed Web of Science ®Google Scholar
• Cobbold JF, Crossey MM, Colman P, et al. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Viral Hepat. 2010;17:537–545.
   PubMed Web of Science ®Google Scholar
• Orlacchio A, Bolacchi F, Petrella MC, et al. Liver contrast enhanced ultrasound perfusion imaging in the evaluation of chronic hepatitis C fibrosis: preliminary results. Ultrasound Med Biol. 2011;37:1–6.
   PubMed Web of Science ®Google Scholar
• Ishibashi H, Maruyama H, Takahashi M, et al. Assessment of hepatic fibrosis by analysis of the dynamic behaviour of microbubbles during contrast ultrasonography. Liver Int. 2010;30:1355–1363.
   PubMed Web of Science ®Google Scholar
• Ishibashi H, Maruyama H, Takahashi M, et al. Demonstration of intrahepatic accumulated microbubble on ultrasound represents the grade of hepatic fibrosis. Eur Radiol. 2012;22:1083–1090.
   PubMed Web of Science ®Google Scholar
• Paternostro C, David E, Novo E, et al. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol. 2010;16:281–288.
   PubMed Web of Science ®Google Scholar
• Bosch J. Vascular deterioration in cirrhosis: the big picture. J Clin Gastroenterol. 2007;41:S247–S253.
   PubMed Web of Science ®Google Scholar
• Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol. 2010;53:976–980.
   PubMed Web of Science ®Google Scholar
• Zipprich A. Hemodynamics in the isolated cirrhotic liver. J Clin Gastroenterol. 2007;41:S254–S258.
   PubMed Web of Science ®Google Scholar
• Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18:281–291.
   PubMed Web of Science ®Google Scholar
• Ridolfi F, Abbattista T, Busilacchi P, et al. Contrast-enhanced ultrasound evaluation of hepatic microvascular changes in liver diseases. World J Gastroenterol. 2012;18:5225–5230.
   PubMed Web of Science ®Google Scholar
• Goyal N, Jain N, Rachapalli V, et al. Non-invasive evaluation of liver cirrhosis using ultrasound. Clin Radiol. 2009;64:1056–1066.
   PubMed Web of Science ®Google Scholar
• Iwao T, Toyonaga A, Oho K, et al. Value of Doppler ultrasound parameters of portal vein and hepatic artery in the diagnosis of cirrhosis and portal hypertension. Am J Gastroenterol. 1997;92:1012–1017.
   PubMed Web of Science ®Google Scholar
• Zironi G, Gaiani S, Fenyves D, et al. Value of measurement of mean portal flow velocity by Doppler flowmetry in the diagnosis of portal hypertension. J Hepatol. 1992;16:298–303.
   PubMed Web of Science ®Google Scholar